Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in refractory status epilepticus
NCT05346666Phase 3Unknown
- Sponsor
- Damanhour University
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised trial of tocilizumab in status epilepticus (SE) (2 arms), sponsored by Damanhour University. Primary endpoints: Interleukin-6 at 3 months, Tumor Necrosis Factor-alpha at 3 months and 2 more. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05346666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346666.